ligands acting on targets

(Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) extracted from patent WO2019156991A1, page 39, has a K i of 0.06 nM. (Rac)-EC5026 can be used for the research of Parkinson's disease and dementia

(Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) extracted from patent WO2019156991A1, page 39, has a K i of 0.06 nM. (Rac)-EC5026 can be used for the research of Parkinson's disease and dementia

(Rac)-Etavopivat ((Rac)-FT-4202) is an isomer of Etavopivat ( HY-139573 ). Etavopivat is an orally active erythrocyte pyruvate kinase-R ( PKR ) activator that can be used in studies of sickle cell disease and other haemoglobinopathies.In

(Rac)-Etavopivat ((Rac)-FT-4202) is an isomer of Etavopivat ( HY-139573 ). Etavopivat is an orally active erythrocyte pyruvate kinase-R ( PKR ) activator that can be used in studies of sickle cell disease and other haemoglobinopathies.In

(Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC 50 =18 nM). Finerenone displays excellent selectivity

(Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC 50 =18 nM). Finerenone displays excellent selectivity

(Rac)-GSK547 is the racemate of GSK547. GSK547 is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIP1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer.Biological

(Rac)-GSK547 is the racemate of GSK547. GSK547 is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIP1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic

(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC 50 of 0.5 nM .In VitroIBT6A (Compound

(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC 50 of 0.5 nM .In VitroIBT6A (Compound

(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC 50 of 0.5 nM .In VitroIBT6A (Compound

(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC 50 of 0.5 nM .In VitroIBT6A (Compound